September 15, 2022 01:17 PM EDT
FDA+

No­var­tis files an­oth­er FDA pe­ti­tion to halt En­tresto com­pe­ti­tion as block­buster fight ap­proach­es

Zachary Brennan

Senior Editor

With promis­es of $5 bil­lion-plus in peak sales for No­var­tis’ En­tresto, the Swiss phar­ma is now pe­ti­tion­ing the FDA for a sec­ond time, hop­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times